COMPANY PROFILE

Chase Pharmaceuticals

Explore full profile

Chase Pharmaceuticals Corporation

United StatesFounded 2007Biotech & Life Sciences

Valuation $100–250M Last recorded · 2016

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Chase Pharmaceuticals

Chase Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative treatments for neurodegenerative diseases, with a primary focus on Alzheimer's disease. The company operates in the healthcare and pharmaceutical market, targeting patients suffering from debilitating neurological conditions. Chase Pharmaceuticals employs a research-driven business model, leveraging advanced scientific methodologies to create effective therapeutic solutions. The company generates revenue through the development, approval, and commercialization of its pharmaceutical products. By addressing unmet medical needs, Chase Pharmaceuticals aims to enhance the quality of life for patients and provide significant advancements in the treatment of neurodegenerative disorders.

MoreLess Source: Dealroom company data

At a glance

Status: Acquired
Founded: 2007
Headquarters: United States
Employees: 1
Open positions: None listed
Dealroom signal: 25.3/100
Industry: Health
Sub-industry: Pharmaceutical
Sector: Biotech & Life Sciences, Biotechnology, Neurology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2c
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

5 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
ACQUISITION✓Exit	Nov 2016	$125M	$125M	Allergan	—
SERIES B✓Equity / VC	Feb 2016	$3.5M	$14M	Undisclosed	—

Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Chase Pharmaceuticals website traffic

Latest recorded traffic for Chase Pharmaceuticals is 0 monthly website visits. Chase Pharmaceuticals's team grew 0% over the past year.

Latest monthly visits0 1-year team growth0%

Monthly website visitsApr 2016–May 2020

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
COCorticaCortica is a provider of advanced neurological therapies for children with autism and other developmental differences	San Diego, United States	Operational	1,444	$255M	$320M
CPCOMPASS PathwaysPsilocybin-based therapies for treatment-resistant mental health conditions	London, United Kingdom	Operational
ADAdvicenneDevelops and markets pediatric drugs for the treatment of neurological diseases of the central nervous system and nephrological disorders	Paris, France	Operational
SHSummit Behavioral HealthcareSummit BHC \| Addiction Treatment in CA, TX, LA, GA & PA	Brentwood, United States	Acquired
ATAchelios TherapeuticsAchelios \| NC based specialty pharmaceutical company	Chapel Hill, United States	Operational
APArchimedes PharmaSpecialty pharmaceutical company developing therapeutics for the treatment of chronic and debilitating illnesses	Reading, United Kingdom	Acquired
NPNuvOx PharmaNuvOx Pharma is a biotechnology company based in Tucson, Arizona that is developing a first-in-class oxygen therapeutic to treat life-threatening diseases where hypoxia plays a role	Tucson, United States	Operational
APAdamas PharmaceuticalsCreate and commercialize a new generation of medicines intended to lessen the burden of chronic neurologic diseases on patients, caregivers and society using its deep understanding of time-dependent biology	Emeryville, United States	Acquired